Market News AIOpen the app

Novo Nordisk shared new results from a 68-week study showing CagriSema helped people lose weight compared to a placebo.

TrialRead the original at pomegra.io
Good for NVO

Patients lost an average of 20.7% and 21.0% of body weight with CagriSema, versus 2.0% with placebo. FDA approval is still pending, but the trial results support Novo Nordisk's obesity-drug plans.

NVO · Novo Nordisk

AI read · Good for NVO

The AI's read

The comparison with placebo gives Novo Nordisk evidence that CagriSema could add another option to its obesity-drug lineup. That may help its effort to remain competitive in obesity care. The drug is not approved yet, and the FDA decision is expected in the fourth quarter of 2026.

Get alerts for NVO

Follow Novo Nordisk (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVO
Free on the App Store and Google Play, or on the web.